As of November 6, 2026, 3 holders' latest Schedule 13D or 13G filings report owning 5% or more of TScan Therapeutics, Inc. The largest reported stake is Lynx1 Capital Management LP's, at 13.1%. 7 filings are on record since July 16, 2025 (Schedule 13G/A, August 14, 2026).
Who owns TScan Therapeutics, Inc.?
Sell to companies like TScan Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Readout Capital, LP · Sole voting: 0 · Shared voting: 3,453,388 · Sole dispositive: 0 · Shared dispositive: 3,453,388 · SCHEDULE 13G, 2026-09-25
- · Reporting person: Lynx1 Capital Management LP · Sole voting: 0 · Shared voting: 20,519,148 · Sole dispositive: 0 · Shared dispositive: 20,519,148 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: Biotechnology Value Fund L P · Sole voting: 0 · Shared voting: 3,649,002 · Sole dispositive: 0 · Shared dispositive: 3,649,002 · SCHEDULE 13G/A, 2026-08-14
- · Holder: Bvf Partners L P · Percent: 9.99% · SCHEDULE 13G/A
- · Holder: Lynx1 Capital Management LP · Percent: 15% · SCHEDULE 13G/A
TScan Therapeutics, Inc. has 7 Schedule 13D or 13G filings on record since 2025-07-16. 3 holders' latest filing reports 5% or more of voting common stock, $0.0001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Layoffs on record: about 66 jobs, latest 2026-09-02 (layoff filings and notices).
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Lynx1 Capital Management LP | 13.1% | 20,519,148 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Bvf Partners L P | 9.99% | 6,417,831 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Readout Capital, LP | 5.4% | 3,453,388 | SCHEDULE 13G, 2026-09-25 | 2026-09-21 |
| Adage Capital Management, L.P. | 2.52% | 1,350,000 | SCHEDULE 13G/A, 2025-08-12 | 2025-06-30 |
| BlackRock, Inc. | 1.8% | 958,373 | SCHEDULE 13G/A, 2025-07-16 | 2025-06-30 |
Holding shares or following this stake? See who's behind TScan Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on TScan Therapeutics, Inc. and the records around it.
TScan Therapeutics, Inc. elsewhere on the record
- Leadership changes Sep 2026
- Layoff notices Sep 2026
- Who owns it
Companies that share a holder
- Readout Capital, LP also filed stake reports on 1 other company: PRECISION BIOSCIENCES INC (Aug 2025)
- Lynx1 Capital Management LP also filed stake reports on 11 other companies: C4 Therapeutics, Inc. (Aug 2026), GH Research PLC (Aug 2026), iBio, Inc. (Aug 2026)
- BIOTECHNOLOGY VALUE FUND L P also filed stake reports on 55 other companies: Frazier Life Sciences Acquisition Corp. II (Oct 2026), Olema Pharmaceuticals, Inc. (Oct 2026), Foghorn Therapeutics Inc. (Oct 2026)
Watch TScan Therapeutics, Inc.
Get an email when TScan Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on TScan Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on TScan Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on TScan Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
11 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 0 | 20,519,148 | 0 | 20,519,148 | SCHEDULE 13G/A, 2026-08-14 |
| Weston Nichols | 0 | 20,519,148 | 0 | 20,519,148 | SCHEDULE 13G/A, 2026-08-14 |
| Biotechnology Value Fund L P | 0 | 3,649,002 | 0 | 3,649,002 | SCHEDULE 13G/A, 2026-08-14 |
| Bvf I Gp LLC | 0 | 3,649,002 | 0 | 3,649,002 | SCHEDULE 13G/A, 2026-08-14 |
| Biotechnology Value Fund Ii LP | 0 | 2,662,237 | 0 | 2,662,237 | SCHEDULE 13G/A, 2026-08-14 |
| Bvf Ii Gp LLC | 0 | 2,662,237 | 0 | 2,662,237 | SCHEDULE 13G/A, 2026-08-14 |
| Biotechnology Value Trading Fund OS LP | 0 | 83,135 | 0 | 83,135 | SCHEDULE 13G/A, 2026-08-14 |
| BVF Partners OS Ltd. | 0 | 83,135 | 0 | 83,135 | SCHEDULE 13G/A, 2026-08-14 |
| Bvf Gp Holdings LLC | 0 | 6,311,239 | 0 | 6,311,239 | SCHEDULE 13G/A, 2026-08-14 |
| Bvf Partners L P | 0 | 6,417,831 | 0 | 6,417,831 | SCHEDULE 13G/A, 2026-08-14 |
| Bvf Inc | 0 | 6,417,831 | 0 | 6,417,831 | SCHEDULE 13G/A, 2026-08-14 |
| Lampert Mark N | 0 | 6,417,831 | 0 | 6,417,831 | SCHEDULE 13G/A, 2026-08-14 |
| Readout Capital, LP | 0 | 3,453,388 | 0 | 3,453,388 | SCHEDULE 13G, 2026-09-25 |
| Readout Capital GP, LLC | 0 | 3,453,388 | 0 | 3,453,388 | SCHEDULE 13G, 2026-09-25 |
| Matthew Smith | 0 | 3,453,388 | 0 | 3,453,388 | SCHEDULE 13G, 2026-09-25 |
The latest filing identifies TScan Therapeutics, Inc. by CUSIP 89854M101 and gives its principal executive office as 830 Winter Street, Waltham, MA 02451 (SCHEDULE 13G, 2026-09-25).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-16 | BlackRock, Inc. | 1.8% | SCHEDULE 13G/A |
| 2025-08-12 | Adage Capital Management, L.P. | 2.52% | SCHEDULE 13G/A |
| 2025-08-14 | Lynx1 Capital Management LP | 15% | SCHEDULE 13G/A |
| 2026-05-15 | Bvf Partners L P | 9.99% | SCHEDULE 13G/A |
| 2026-08-14 | Lynx1 Capital Management LP | 13.1% | SCHEDULE 13G/A |
| 2026-08-14 | Bvf Partners L P | 9.99% | SCHEDULE 13G/A |
| 2026-09-25 | Readout Capital, LP | 5.4% | SCHEDULE 13G |
Questions about who owns TScan Therapeutics, Inc.
Who owns TScan Therapeutics, Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of TScan Therapeutics, Inc.: Lynx1 Capital Management LP (13.1%, Schedule 13G/A, filed 2026-08-14), Bvf Partners L P (9.99%, Schedule 13G/A, filed 2026-08-14) and Readout Capital, LP (5.4%, Schedule 13G, filed 2026-09-25).
Who are the largest shareholders of TScan Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of TScan Therapeutics, Inc. on this page are Lynx1 Capital Management LP (13.1%), Bvf Partners L P (9.99%) and Readout Capital, LP (5.4%).
When did Lynx1 Capital Management LP buy into TScan Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Lynx1 Capital Management LP on this page is the Schedule 13G/A, filed 2025-08-14, reporting 15%; its latest, Schedule 13G/A filed 2026-08-14, reports 13.1%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 7 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for TScan Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 16, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| September 11, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| September 2, 2026 | Leadership change: Jason A. Amello departs, Chief Financial Officer | — | Leadership changes | Source |
| April 2, 2026 | Leadership change: Leiden Dworak departs, Vice President, and 1 more | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for TScan Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.